Icon

LAZCLUZE (NDA219008)- (EQ 80MG BASE,EQ 240MG BASE)

LAZERTINIB MESYLATE JANSSEN BIOTECH
EQ 80MG BASE,EQ 240MG BASE
No No
2041-Aug-01 2029-Aug-19
None None
None No
LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 80MG BASE ** ** - - -
EQ 240MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.